118 related articles for article (PubMed ID: 31337259)
1. Clinicopathological significance and prognostic implication of programmed death-1 ligand 2 expression in colorectal cancer.
Pyo JS; Son BK; Chung KH; Oh IH
Int J Biol Markers; 2019 Sep; 34(3):276-283. PubMed ID: 31337259
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer.
Ko YS; Pyo JS
Int J Biol Markers; 2019 Jun; 34(2):132-138. PubMed ID: 30852949
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy.
Huang KC; Chiang SF; Chen TW; Chen WT; Yang PC; Ke TW; Chao KSC
Sci Rep; 2020 Dec; 10(1):22330. PubMed ID: 33339860
[TBL] [Abstract][Full Text] [Related]
4. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy.
Tanaka K; Miyata H; Sugimura K; Kanemura T; Hamada-Uematsu M; Mizote Y; Yamasaki M; Wada H; Nakajima K; Takiguchi S; Mori M; Doki Y; Tahara H
Cancer Sci; 2016 Jun; 107(6):726-33. PubMed ID: 27015293
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression.
Pyo JS; Ko SH; Ko YS; Kim NY
Pathol Res Pract; 2020 Feb; 216(2):152764. PubMed ID: 31836325
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.
Takamori S; Takada K; Azuma K; Jogo Y; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Toyokawa G; Hirai F; Tagawa T; Okamoto I; Nakanishi Y; Kawahara A; Akiba J; Oda Y; Maehara Y
Anticancer Res; 2018 Oct; 38(10):5903-5907. PubMed ID: 30275217
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2.
Ariafar A; Ghaedi M; Rezaeifard S; Shahriari S; Zeighami S; Ghaderi A; Faghih Z
Mol Immunol; 2020 Aug; 124():35-41. PubMed ID: 32512320
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer.
Wu Z; Yang L; Shi L; Song H; Shi P; Yang T; Fan R; Jiang T; Song J
Biomed Res Int; 2019; 2019():8014627. PubMed ID: 31275983
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
Calik I; Calik M; Turken G; Ozercan IH; Dagli AF; Artas G; Sarikaya B
Medicina (Kaunas); 2019 Oct; 55(11):. PubMed ID: 31683723
[No Abstract] [Full Text] [Related]
10. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
12. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
[TBL] [Abstract][Full Text] [Related]
13. Impact of sidedness of colorectal cancer on tumor immunity.
Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
[TBL] [Abstract][Full Text] [Related]
14. Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer.
Enkhbat T; Nishi M; Takasu C; Yoshikawa K; Jun H; Tokunaga T; Kashihara H; Ishikawa D; Shimada M
Anticancer Res; 2018 Jun; 38(6):3367-3373. PubMed ID: 29848685
[TBL] [Abstract][Full Text] [Related]
15. PD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer.
Zengin M; Zergeroğlu S; Okcu O; Benek S
Cell Oncol (Dordr); 2021 Apr; 44(2):423-432. PubMed ID: 33469839
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer.
Xue C; Zhu D; Chen L; Xu Y; Xu B; Zhang D; Jiang J
Transl Cancer Res; 2019 Feb; 8(1):111-119. PubMed ID: 35116740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]